Frequently asked questions about pneumococcal meningitis
What is the survival rate for pneumococcal meningitis cases?
Most people who get pneumococcal meningitis will survive. The likelihood of survival differs depending on your age and where in the world you live. Very young babies and older people are less likely to survive than other age groups.
In some countries around two out of ten people who get pneumococcal meningitis will die, but in others as many as half of those affected may die from the disease.9,10,11,12,13,14
Is pneumococcal meningitis bacterial or viral?
Pneumococcal meningitis is caused by bacteria called Streptococcus pneumoniae, commonly called pneumococcal bacteria. There are at least 100 different strains (serotypes) of pneumococcal bacteria, but only a minority of these are responsible for causing most disease worldwide.
Am I at risk of spreading or contracting the disease if I've been in contact with a patient with pneumococcal meningitis?
In general the answer is no. Pneumococcal meningitis is not usually considered to be contagious, and most cases occur in isolation. The risk of getting the disease is very low, even if you have been in contact with someone with pneumococcal meningitis.
It has been known for clusters of cases of severe pneumococcal disease to occur in closed settings such as hospital wards, nurseries and care homes. The UK has produced guidance to help with the management of such clusters in the UK setting.15 Depending on the circumstances, people who have been in contact with a case might be offered preventative antibiotics or a vaccine.
Large outbreaks of pneumococcal meningitis due to a particular serotype (serotype 1) have been reported from within the meningitis belt region of Africa,16 but such outbreaks are unheard of in the rest of the world.
What is Meningitis Research Foundation doing to defeat pneumococcal meningitis?
Meningitis Research Foundation is part of WHO's Technical Taskforce for the Global Road Map to Defeat Meningitis by 2030. This taskforce aims to make more affordable broader coverage pneumococcal vaccines available globally by 2026 to protect as many people as possible.
Research we have funded has made some important contributions towards achieving this goal. Meningitis Research Foundation has funded early-stage research to help discover several broad coverage pneumococcal vaccine candidates. Some of these are still being pursued today.
Read more about Meningitis Research Foundation funded research.